Logo image of INSM

INSMED INC (INSM) Stock Fundamental Analysis

USA - NASDAQ:INSM - US4576693075 - Common Stock

142.96 USD
-0.18 (-0.13%)
Last: 9/16/2025, 11:35:00 AM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to INSM. INSM was compared to 540 industry peers in the Biotechnology industry. While INSM seems to be doing ok healthwise, there are quite some concerns on its profitability. INSM is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

INSM had negative earnings in the past year.
INSM had a negative operating cash flow in the past year.
In the past 5 years INSM always reported negative net income.
In the past 5 years INSM always reported negative operating cash flow.
INSM Yearly Net Income VS EBIT VS OCF VS FCFINSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

INSM has a Return On Assets (-41.71%) which is comparable to the rest of the industry.
INSM has a Return On Equity of -82.76%. This is comparable to the rest of the industry: INSM outperforms 51.48% of its industry peers.
Industry RankSector Rank
ROA -41.71%
ROE -82.76%
ROIC N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INSM Yearly ROA, ROE, ROICINSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

With an excellent Gross Margin value of 75.72%, INSM belongs to the best of the industry, outperforming 83.15% of the companies in the same industry.
In the last couple of years the Gross Margin of INSM has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for INSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
INSM Yearly Profit, Operating, Gross MarginsINSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
INSM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for INSM has been increased compared to 5 years ago.
Compared to 1 year ago, INSM has an improved debt to assets ratio.
INSM Yearly Shares OutstandingINSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
INSM Yearly Total Debt VS Total AssetsINSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

INSM has an Altman-Z score of 11.75. This indicates that INSM is financially healthy and has little risk of bankruptcy at the moment.
INSM has a better Altman-Z score (11.75) than 87.41% of its industry peers.
INSM has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
INSM has a Debt to Equity ratio of 0.45. This is in the lower half of the industry: INSM underperforms 72.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z 11.75
ROIC/WACCN/A
WACC9.49%
INSM Yearly LT Debt VS Equity VS FCFINSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

INSM has a Current Ratio of 6.68. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.68, INSM is doing good in the industry, outperforming 66.85% of the companies in the same industry.
INSM has a Quick Ratio of 6.33. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
INSM has a better Quick ratio (6.33) than 65.56% of its industry peers.
Industry RankSector Rank
Current Ratio 6.68
Quick Ratio 6.33
INSM Yearly Current Assets VS Current LiabilitesINSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The earnings per share for INSM have decreased by -5.94% in the last year.
The Revenue has grown by 21.15% in the past year. This is a very strong growth!
The Revenue has been growing by 21.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.37%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%18.9%

3.2 Future

INSM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.02% yearly.
INSM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.71% yearly.
EPS Next Y-0.1%
EPS Next 2Y16.82%
EPS Next 3Y22.85%
EPS Next 5Y27.02%
Revenue Next Year29.87%
Revenue Next 2Y71.12%
Revenue Next 3Y76.22%
Revenue Next 5Y64.71%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INSM Yearly Revenue VS EstimatesINSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B 8B
INSM Yearly EPS VS EstimatesINSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

INSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INSM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INSM Price Earnings VS Forward Price EarningsINSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INSM Per share dataINSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

INSM's earnings are expected to grow with 22.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.82%
EPS Next 3Y22.85%

More info and screens

0

5. Dividend

5.1 Amount

INSM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INSMED INC

NASDAQ:INSM (9/16/2025, 11:35:00 AM)

142.96

-0.18 (-0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-29 2025-10-29
Inst Owners109.14%
Inst Owner Change0.04%
Ins Owners0.82%
Ins Owner Change-9.7%
Market Cap30.22B
Analysts85.38
Price Target156.83 (9.7%)
Short Float %5.06%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.66%
Min EPS beat(2)-28.87%
Max EPS beat(2)-4.46%
EPS beat(4)0
Avg EPS beat(4)-11.73%
Min EPS beat(4)-28.87%
Max EPS beat(4)-2.38%
EPS beat(8)2
Avg EPS beat(8)-10.89%
EPS beat(12)2
Avg EPS beat(12)-14.95%
EPS beat(16)4
Avg EPS beat(16)-10.08%
Revenue beat(2)1
Avg Revenue beat(2)0.13%
Min Revenue beat(2)-1.17%
Max Revenue beat(2)1.43%
Revenue beat(4)1
Avg Revenue beat(4)-0.42%
Min Revenue beat(4)-1.53%
Max Revenue beat(4)1.43%
Revenue beat(8)2
Avg Revenue beat(8)-1.08%
Revenue beat(12)3
Avg Revenue beat(12)-0.69%
Revenue beat(16)5
Avg Revenue beat(16)-0.1%
PT rev (1m)33.03%
PT rev (3m)58.31%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)-0.89%
EPS NY rev (1m)-3.61%
EPS NY rev (3m)-2.81%
Revenue NQ rev (1m)-0.34%
Revenue NQ rev (3m)0.2%
Revenue NY rev (1m)2.9%
Revenue NY rev (3m)2.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 75.9
P/FCF N/A
P/OCF N/A
P/B 24.18
P/tB 28.57
EV/EBITDA N/A
EPS(TTM)-5.71
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-4.11
FCFYN/A
OCF(TTM)-4
OCFYN/A
SpS1.88
BVpS5.91
TBVpS5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.71%
ROE -82.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.72%
FCFM N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 159.38%
Cap/Sales 6.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.68
Quick Ratio 6.33
Altman-Z 11.75
F-Score4
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)113.37%
Cap/Depr(5y)86.53%
Cap/Sales(3y)4.8%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.37%
EPS Next Y-0.1%
EPS Next 2Y16.82%
EPS Next 3Y22.85%
EPS Next 5Y27.02%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%18.9%
Revenue Next Year29.87%
Revenue Next 2Y71.12%
Revenue Next 3Y76.22%
Revenue Next 5Y64.71%
EBIT growth 1Y-44.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.82%
EBIT Next 3Y23.47%
EBIT Next 5YN/A
FCF growth 1Y-82.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.77%
OCF growth 3YN/A
OCF growth 5YN/A